netFormulary Chelsea and Westminster Hospital NHS
NHS Foundation Trust  
 Search
 Results

Looking for Abatacept found 19 matches

Formulary items 8 matches
   
Open monograph to display formulary status BNF Category
  Abatacept  (Orencia®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Adalimumab  (Humira® Amgevita®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Certolizumab Pegol  (Cimzia®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Etanercept  (Enbrel®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Golimumab  (Simponi®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Infliximab  (Remicade®)
(For use in line with NICE guidance) 		Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Rituximab  (MabThera®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Tocilizumab  (RoActemra®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)


 
netFormulary